RhoC a new target for therapeutic vaccination against metastatic cancer

Lynn Wenandy, Rikke Baek Sørensen, Inge Marie Svane, Per Thor Straten, Mads Hald Andersen


Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers. Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of "therapeutic" vaccines. The over-expression of RhoC in cancer and the fact that immune escape by down regulation or loss of expression of this protein would reduce the morbidity and mortality of cancer makes RhoC a very attractive target for anti-cancer immunotherapy. Herein, we describe an HLA-A3 restricted epitope from RhoC, which is recognized by cytotoxic T cells. Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies.

Original languageEnglish
JournalCancer Immunology and Immunotherapy
Issue number12
Pages (from-to)1871-8
Number of pages8
Publication statusPublished - Dec 2008


  • Antigens, Neoplasm/immunology
  • Cancer Vaccines/immunology
  • Carcinoma, Renal Cell/immunology
  • Cells, Cultured
  • Epitopes, T-Lymphocyte/immunology
  • HLA-A3 Antigen/immunology
  • Humans
  • Kidney Neoplasms/immunology
  • Melanoma/immunology
  • Neoplasms/immunology
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes, Cytotoxic/immunology
  • rho GTP-Binding Proteins/immunology
  • rhoC GTP-Binding Protein


Dive into the research topics of 'RhoC a new target for therapeutic vaccination against metastatic cancer'. Together they form a unique fingerprint.

Cite this